Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Roxana Schaab, Christina Ganster, PhD, Sascha Dierks, PhD, Katayoon Shirneshan, PhD, Marc Talló Parra, Roman Martin, PhD, Ulrich Germing, Uwe Platzbecker, MD, Frank Lange, MD, Nicolaus Kroeger, MD, Konstanze Döhner, MD, Bertram Glass, MD, Maike Nickelsen, MD, Reingard Stuhlmann, MD, Lorenz H. Truemper, MD, Julie Schanz, MD, Ulrike Bacher, MD, Detlef Haase, MD

Blood (2016) 128 (22): 2001.

https://doi.org/10.1182/blood.V128.22.2001.2001

Published: 2016

Journal Articles

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Norbert Schmitz, MD PhD, Maike Nickelsen, MD, Marita Ziepert, PhD, Mathias Haenel, MD, Andreas Viardot, MD, Martin H. Dreyling, MD PhD, Peter Borchmann, MD, Carsten Bokemeyer, MD, Christian Peschel, MD, Hans-Heinrich Wolf, MD, Rolf Mahlberg, MD, Michael Pfreundschuh, MD, Bertram Glass, MD

Blood (2015) 126 (23): 474.

https://doi.org/10.1182/blood.V126.23.474.474

Published: 2015

Journal Articles

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Kerry J. Savage, MDMSc, Samira Zeynalova, PhD, Roopesh R. Kansara, MD, Maike Nickelsen, MD, Diego Villa, MDMPH, Laurie H. Sehn, MDMPH, Marita Ziepert, David W. Scott, MBChB, PhD, Michael Pfreundschuh, MD PhD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Bertram Glass, MD, Markus Loeffler, Prof MDPhD, Norbert Schmitz

Blood (2014) 124 (21): 394.

https://doi.org/10.1182/blood.V124.21.394.394

Published: 2014

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Anke Görlitz, Peter Dreger, MD, Jörg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1974.

https://doi.org/10.1182/blood.V112.11.1974.1974

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Maike Nickelsen, MD, Carmen Canals, Sr., Charalampia Kyriakou, MD, PhD, Norbert Schmitz, MD, PhD, Agnes Buzyn, MD, Monika Engelhardt, MD, PhD, Bertram Glass, MD, PhD, Eulogio Conde, MD, Armando Lopez-Guillermo, MD, Gerard Socie, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 974.

https://doi.org/10.1182/blood.V112.11.974.974

Published: 2008

Journal Articles

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Maike Nickelsen, MD, Carmen Canals, Sr., MD, Norbert Schmitz, MD, PhD, Charalampia Kyriakou, MD, PhD, Monika Engelhardt, MD, PhD, Thomas Relander, MD, Werner Linkesch, MD, PhD, Vladimir Koza, MD, Giovanna Meloni, MD, Armando Lopez-Guillermo, MD, Karel Indrac, MD, Dolores Caballero, MD, Hannes Wandt, MD, PhD, Niklas Theorin, MD, Bertram Glass, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 774.

https://doi.org/10.1182/blood.V112.11.774.774

Published: 2008

Journal Articles

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Peter Dreger, MD, Martin Gramatzki, MD, Joerg Schubert, MD, Gerald G. Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 3043.

https://doi.org/10.1182/blood.V110.11.3043.3043

Published: 2007

Journal Articles

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Michael Rieger, MD, Mathias Witzens-Harig, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Maike Nickelsen, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD

Blood (2007) 110 (11): 5106.

https://doi.org/10.1182/blood.V110.11.5106.5106

Published: 2007

NARROW

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only